ArticleFrontiers in computational neuroscience2026
Study on the cognitive effects of eye movement desensitization and reprocessing: proposed active mechanisms.
Article in Frontiers in computational neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Post-traumatic stress disorder (PTSD) is characterized by intrusive memories and an impaired resilience framework, which often leads to chronic psychological distress. Eye Movement Desensitization and Reprocessing (EMDR) is an emerging therapeutic approach targeting PTSD, yet the precise neurobiological mechanisms remain inadequately defined. Recent studies suggest immune modulation, mainly through molecules such as Interleukin-6 (IL-6), Interleukin-10 (IL-10), Neuropeptide Y (NPY), and Oxytocin (OXY), as well as additional proteins, may play a key role in longitudinal outcomes. This study investigated the roles of immune factors, systemic interactions, and neurobiological functions, including the Default Mode Network (DMN) and B-cell regulation, in PTSD remission and EMDR efficacy. Methodology: A systematic dry-lab analytical approach was employed using Artificial Neural Network (ANN) modeling and dynamic pathway analysis to reveal neurobiological factors, immune function, and neural network differences involved in PTSD remission and EMDR functionality. Publicly available gene expression datasets were analyzed, focusing on key pathways, interactions, and gene loci related to immune regulation, neurobiological modulation, and inflammatory response. Key molecules, including IL-6, IL-10, NPY, and OXY, were examined for potential contributions to neurobiological resilience, therapeutic response, and immune function in response to adverse stimuli. Results: The ANN analysis revealed that immunological function, notably through IL-10 and B-cell activity, plays a prominent role in PTSD remission, EMDR outcomes, and resilience. IL-10 emerged as central to B-cell differentiation and proliferation regarding trauma and resilience, indicating its potential as a biomarker for PTSD within the first year of symptom onset. Additional analyses implicated IL-6 and NPY as critical to longitudinal neurobiological resilience mechanisms. Interestingly, while OXY was initially classified as significant for social bonding and PTSD remission, analysis showed this gene only played a secondary mediating role, aligning with recent findings that OXY is not strictly necessary for prosocial outcomes such as PTSD remission. Conclusion: This study suggests that IL-10, IL-6, and NPY are key neuroimmune modulators in PTSD remission and may explain EMDR functionality. Immunologic activity may also explain variations in EMDR outcomes, such as therapeutic success, resistance, and relapse rates. These findings underscore the potential of targeted co-occurring immunotherapies, possible objective PTSD tests, potential objective measures for EMDR outcomes, and personalized approaches for enhanced treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.